Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells $41,541.60 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 86,545 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the sale, the director now owns 3,170,231 shares in the company, valued at $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total value of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total value of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Stock Up 8.3 %

IVVD opened at $0.48 on Friday. Invivyd, Inc. has a 52 week low of $0.40 and a 52 week high of $5.20. The business has a 50 day moving average price of $0.70 and a two-hundred day moving average price of $0.95. The company has a market cap of $57.42 million, a PE ratio of -0.24 and a beta of 0.53.

Institutional Investors Weigh In On Invivyd

Large investors have recently modified their holdings of the stock. Proficio Capital Partners LLC acquired a new position in Invivyd in the 3rd quarter valued at $27,000. XTX Topco Ltd boosted its holdings in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after acquiring an additional 15,376 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in shares of Invivyd during the second quarter worth about $86,000. Rhumbline Advisers raised its holdings in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Invivyd in the second quarter valued at about $115,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on IVVD. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Morgan Stanley dropped their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. HC Wainwright reduced their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.